Cerenovus’ Emboguard Balloon Guide Catheter Launched for Acute Ischemic Stroke Treatment

February 7, 2022—Cerenovus, part of Johnson & Johnson Medical Devices Companies, announced the launch of Emboguard, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke.

Cerenovus will debut the Emboguard at the International Stroke Conference 2022 held February 9-11 in New Orleans, Louisiana.

According to the company, the Emboguard device is designed to optimize the removal of clots by controlling blood flow locally during mechanical thrombectomy procedures. Balloon guide catheters increase first-pass recanalization, reduce procedure time, and reduce the odds of clot fragments breaking off and causing distal emboli.

“Without timely and effective treatment of stroke, patients can suffer from lifelong disability or dependency,” commented David Fiorella, MD, in the Cerenovus press release. “The benefits of balloon guide catheters are becoming increasingly recognized for their ability to maximize patient outcomes. By adding this innovation to their Stroke Solutions portfolio, Cerenovus will be arming physicians with the tools they need to better serve our patients, potentially increasing the chances to live a functional and fulfilling life post-stroke.” Dr. Fiorella is Director of the Cerebrovascular Center at Stony Brook University Hospital in Stony Brook, New York.

Cerenovus Stroke Solutions was launched in 2020 and now includes the Embotrap III revascularization device, the Prowler EX microcatheter, the Cerenovus large-bore catheter, the Emboguard balloon guide catheter, and the Cerebase guide sheath, stated the company.